Security Snapshot

Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) Institutional Ownership

CUSIP: 90466Y202

13F Institutional Holders and Ownership History from Q2 2025 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

78

Shares (Excl. Options)

11.6MFull value: 11,598,299 · shares · 30 Jun 2026

Price

$4.69

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+1,808,014
Value change
+$6,230,711
Number of holders
78
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
48,611,201
SEC-reported price per share
$4.19
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 90466Y202.
  • 78 institutions reported positions in Q2 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 51 to 78 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $65.21MFull value: $65,206,284 · USD · 31 Mar 2026
    to
    $54.46MFull value: $54,460,666 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 78 institutions filings for Q2 2026.

Open SEC evidence

Security key

90466Y202

13F reference period

Q2 2026

13F holders

78

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
UNCY
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vivo Opportunity Fund Holdings, L.P. 10% 0% $25,543,922 -$6,521,958 4,856,259 -20% Vivo Opportunity Fund Holdings, L.P. 30 Jun 2026
Nantahala Capital Management, LLC 10% 0% $14,769,186 +$2,770,915 2,807,830 +23% Nantahala Capital Management, LLC 30 Jun 2026
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $18,066,979 +$2,681,929 2,801,082 +17% RA Capital Management, L.P. 31 Mar 2026
BIOTECHNOLOGY VALUE FUND L P 10% $7,439,864 1,417,117 BVF PARTNERS L P/IL 30 Jun 2025
BlackRock, Inc. 5.3% $6,628,757 1,413,381 BlackRock, Inc. 30 Jun 2026
Octagon Capital Advisors LP 4.7% -17% $5,870,000 1,000,000 0% Octagon Capital Advisors LP 31 Dec 2025
GREAT POINT PARTNERS LLC 4.5% -29% $3,472,993 796,558 0% Great Point Partners, LLC 30 Sep 2025
INTEGRATED CORE STRATEGIES (US) LLC 1% -75% $2,087,497 -$6,930,313 271,456 -77% Millennium Management LLC 30 Jun 2026
As of 30 Jun 2026, 78 institutional investors reported holding
11.6MFull value: 11,598,299 · shares · 30 Jun 2026
shares of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY). This represents 24% of the company’s total
48.61MFull value: 48,611,201 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
22%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 2.9% 1,413,381 +3837% 0% $6,628,757
Nantahala Capital Management, LLC 2.9% 1,401,447 +49% 0.4% $6,572,786
VANGUARD CAPITAL MANAGEMENT LLC 2.2% 1,071,481 +32% 0% $5,025,246
Octagon Capital Advisors LP 2.1% 1,000,000 0% 0.43% $4,690,000
GEODE CAPITAL MANAGEMENT, LLC 1.2% 564,019 +177% 0% $2,646,043
Vivo Capital, LLC 1.1% 550,000 -69% 0.24% $2,579,500
MARSHALL WACE, LLP 1.1% 547,862 +254% 0% $2,569,473
Logos Global Management LP 0.97% 473,563 0% 0.1% $2,221,010
STATE STREET CORP 0.93% 450,162 +463% 0% $2,111,260
Diametric Capital, LP 0.77% 374,132 +366% 0.19% $1,754,679
J. Goldman & Co LP 0.67% 327,345 0.05% $1,535,248
DIADEMA PARTNERS LP 0.62% 303,676 +186% 0.54% $1,424,240
MILLENNIUM MANAGEMENT LLC 0.56% 271,456 -81% 0% $1,273,129
Dauntless Investment Group, LLC 0.44% 214,000 +45% 1.7% $1,003,660
CITIGROUP INC 0.38% 182,654 +18265300% 0% $856,647
NORTHERN TRUST CORP 0.37% 181,930 +406% 0% $853,252
VANGUARD PORTFOLIO MANAGEMENT LLC 0.35% 169,196 0% $793,529
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.33% 160,039 -20% 0% $750,583
Jump Financial, LLC 0.31% 153,000 0.01% $717,570
VANGUARD FIDUCIARY TRUST CO 0.31% 148,965 +47% 0% $698,646
GOLDMAN SACHS GROUP INC 0.3% 145,304 +436% 0% $681,475
DIMENSIONAL FUND ADVISORS LP 0.29% 140,692 -1.6% 0% $659,846
Caption Management, LLC 0.23% 110,000 0.02% $515,900
MORGAN STANLEY 0.23% 109,645 -42% 0% $514,235
Seven Fleet Capital Management LP 0.21% 103,400 +86% 0.09% $521,136

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
6
Headline period
Q2 2026
Rows shown
1-6 of 6
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 123,345 $517,083 +$325,064 $4.70 15
2026 Q2 11,598,299 $54,460,666 +$6,230,711 $4.69 78
2026 Q1 9,906,082 $65,206,284 +$10,118,070 $6.58 51
2025 Q4 8,144,623 $47,021,122 +$10,346,527 $5.77 34
2025 Q3 6,285,927 $27,416,349 +$4,969,291 $4.36 30
2025 Q2 5,144,083 $24,616,897 +$24,616,897 $4.77 19
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .